Business
Nimbus Therapeutics Announces Research Collaboration and License Agreement with Lilly for Novel Oral Obesity Treatment
BOSTON, January 06, 2026--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it has entered into a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company ("Lilly") to develop a novel oral treatment for obesity and other metabolic diseases.
About this update from Eli Lilly And Company
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":240,"url":"https://media.zenfs.com/en/business-wire.com/902cc921431246d14ccd3804173e2b35"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7kgwNDVrDSe2qsXohK9fkg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQ4MDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/902cc921431246d14ccd3804173e2b35","width":480,"height":240}},"lazy":false},{"type":"text","content":"-- New collaboration follows previous Lilly and Nimbus AMPK research collaboration in cardiometabolic disease --","length":112,"tagName":"p","attribs":{}},{"type":"text","content":"BOSTON, January 06, 2026--(BUSINESS WIRE)--Nimbus Therapeutics, LLC ("Nimbus Therapeutics" or "Nimbus"), a drug discovery company developing breakthrough medicines through its AI-enhanced computational drug discovery engine, today announced it has entered into a multi-year research collaboration and exclusive, worldwide license agreement with Eli Lilly and Company ("Lilly") to develop a novel oral treatment for obesity and other metabolic diseases.","length":482,"tagName":"p"},{"type":"text","content":"This new collaboration follows the previous collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases. The companies will now apply Nimbus' computational chemistry and structure-based drug design approach to an early-stage, small molecule discovery program addressing a significant unmet need in obesity.","length":332,"tagName":"p"},{"type":"text","content":""We are pleased to deepen our collaboration with Nimbus, a team that has demonstrated exceptional ability to tackle complex drug discovery challenges," said Ruth Gimeno, Group Vice President, Diabetes and Metabolic Research and Development at Lilly. "Working together to develop this novel obesity therapy represents an important addition to Lilly's efforts to advance innovative treatment options for patients with metabolic disorders."","length":461,"tagName":"p"},{"type":"text","content":""At Nimbus, computational scientists, medicinal chemists, pharmacologists and translational biologists work together to integrate AI-driven predictive models with structure-based design to develop novel small molecules with best-in-cla...